Metotrexate Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This halts the replication of rapidly dividing cells such as immune cells in autoimmune disease and cancer cells in malignancies, providing both immunosuppressive and antineoplastic effects.

The dose of Metotrexate Ebewe is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Only a qualified health professional should determine the appropriate dosing schedule.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Metotrexate Ebewe product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with biologic agents used for rheumatoid arthritis or psoriasis, methotrexate is a small‑molecule drug that is less expensive but may have a broader side‑effect profile, especially concerning bone‑marrow and liver toxicity. In oncology, it is often combined with other chemotherapeutics, whereas alternatives like azacitidine target different pathways.

Metotrexate Ebewe should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold chain to preserve stability.

The medication is supplied as a sterile injectable solution and can be given by intramuscular, intravenous or subcutaneous injection. The route, volume and infusion rate are determined by the prescriber based on the clinical indication and patient tolerance.

The most critical adverse events include bone‑marrow suppression leading to pancytopenia, severe liver injury or fibrosis, pulmonary toxicity such as interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for blood counts, liver function and respiratory symptoms.

Metotrexate Ebewe is contraindicated in pregnant or breastfeeding women, patients with severe hepatic or renal impairment, those with active infections, and individuals with known hypersensitivity to methotrexate or any excipients in the formulation. Caution is also advised for patients with a history of lung disease.